BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ahmed OA, Elsebaey MA, Fouad MHA, Elashry H, Elshafie AI, Elhadidy AA, Esheba NE, Elnaggar MH, Soliman S, Abd-Elsalam S. Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection. Infect Drug Resist. 2018;11:441-445. [PMID: 29628768 DOI: 10.2147/idr.s160593] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 5.8] [Reference Citation Analysis]
Number Citing Articles
1 Elbedewy TA, Elsebaey MA, Elshweikh SA, Elashry H, Abd-Elsalam S. Predictors for eltrombopag response in patients with hepatitis C virus-associated thrombocytopenia. Ther Clin Risk Manag 2019;15:269-74. [PMID: 30804674 DOI: 10.2147/TCRM.S186106] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 El-sisi AE, Zakaria S. Potential Anti-Fibrotic Effect of Direct Acting Antiviral Drugs on CCl4 Induced Hepatic Fibrosis in Rats. Egyptian Journal of Basic and Clinical Pharmacology 2019;9. [DOI: 10.32527/2019/101414] [Reference Citation Analysis]
3 Umutesi J, Liu CY, Penkunas MJ, Makuza JD, Ntihabose CK, Umuraza S, Niyikora J, Serumondo J, Gupta N, Nsanzimana S. Screening a nation for hepatitis C virus elimination: a cross-sectional study on prevalence of hepatitis C and associated risk factors in the Rwandan general population. BMJ Open 2019;9:e029743. [PMID: 31272986 DOI: 10.1136/bmjopen-2019-029743] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
4 Omran D, Alboraie M, Zayed RA, Wifi MN, Naguib M, Eltabbakh M, Abdellah M, Sherief AF, Maklad S, Eldemellawy HH, Saad OK, Khamiss DM, El Kassas M. Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations. World J Gastroenterol 2018; 24(38): 4330-4340 [PMID: 30344418 DOI: 10.3748/wjg.v24.i38.4330] [Cited by in CrossRef: 79] [Cited by in F6Publishing: 64] [Article Influence: 19.8] [Reference Citation Analysis]
5 Debnath P, Chandnani S, Rathi P, Nair S, Junare P, Udgirkar S, Singh A, Contractor Q. A new model to predict response to direct-acting antiviral therapy in decompensated cirrhotics due to hepatitis C virus. Clin Exp Hepatol 2020;6:253-62. [PMID: 33145432 DOI: 10.5114/ceh.2020.99525] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Naguib GG, Michael TG, Elshazly Y, Wahdan MM, Mostafa A, Ahmed OA, Dabbous H, Aly HIS, Shaker MK, Elbaz HS, El-Serafy M, Doss W, Abd-Elsalam S, El-Sayed MH. The outcome of re-treatment of relapsed hepatitis C virus infection in a resource-limited setting. Virusdisease 2021;32:582-8. [PMID: 34631983 DOI: 10.1007/s13337-021-00712-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Abo-Amer YE, Abd-Elsalam S, Eldosoky H, ELShenawy AK, Awny S, Elagawy W, Abgeegy ME, Elsergany HF, Elashry H, Negm MS. Declining prevalence of hepatitis C virus among university students in one of the main governorates in Egypt. Infect Drug Resist 2018;11:2435-41. [PMID: 30538509 DOI: 10.2147/IDR.S183462] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
8 Abo-Amer YE, Badawi R, El-Abgeegy M, Elsergany HF, Mohamed AA, Mostafa SM, Alegaily HS, Soliman S, Elnawasany S, Abd-Elsalam S. Quadruple Therapy Offers High SVR Rates in Patients with HCV Genotype 4 with Previous Treatment Failure. Adv Virol 2020;2020:9075905. [PMID: 32774374 DOI: 10.1155/2020/9075905] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
9 Sultan S, El-Mowafy M, Elgaml A, El-Mesery M, El Shabrawi A, Elegezy M, Hammami R, Mottawea W. Alterations of the Treatment-Naive Gut Microbiome in Newly Diagnosed Hepatitis C Virus Infection. ACS Infect Dis 2021;7:1059-68. [PMID: 33119247 DOI: 10.1021/acsinfecdis.0c00432] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
10 Salum GM, Dawood RM, Abd El-Meguid M, Ibrahim NE, Abdel Aziz AO, El Awady MK. Correlation between IL28B/TLR4 genetic variants and HCC development with/without DAAs treatment in chronic HCV patients. Genes Dis 2020;7:392-400. [PMID: 32884993 DOI: 10.1016/j.gendis.2019.05.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
11 Tawfik AK, Amin AM, Yousef M, El-Sayd NM, Elashry H, Elkadeem M, Abd-Elsalam S. IL-1α correlates with severity of hepatitis C virus-related liver diseases. J Inflamm Res 2018;11:289-95. [PMID: 30022847 DOI: 10.2147/JIR.S166564] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
12 Alian SM, Wahba MO, Gomaa AF, Khalil SS. The efficacy and safety of direct-acting antiviral drugs in the management of hepatitis C virus-related arthritis. Egypt Rheumatol Rehabil 2020;47. [DOI: 10.1186/s43166-020-00021-6] [Reference Citation Analysis]
13 Tawfik AK, Helmy A, Yousef M, Abou-Saif S, Kobtan A, Asaad E, Abd-Elsalam S. Copeptin as a novel marker predicting prognosis of liver cirrhosis and its major complications. Hepat Med 2018;10:87-93. [PMID: 30214326 DOI: 10.2147/HMER.S174267] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
14 Saleh AM, Hassan EA, Gomaa AA, El Baz TM, El-Abgeegy M, Seleem MI, Abo-Amer YE, Elsergany HF, Mahmoud EIE, Abd-Elsalam S. Impact of pre-transplant infection management on the outcome of living-donor liver transplantation in Egypt. Infect Drug Resist 2019;12:2277-82. [PMID: 31413604 DOI: 10.2147/IDR.S208954] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]